Bionor Pharma

bionor's mission is to enable the immune system to fight hiv infection. bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further advancing its therapeutic vaccine vacc-4x and vacc-c5 in combination with other agents towards a functional cure. the company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. in december 2015, bionor announced that the hiv trial reduc with vacc-4x and romidepsin successfully met its primary endpoint by reducing latent hiv reservoir and further demonstrated control of viral load. bionor retains full ownership rights to the hiv immunotherapy vacc-4x and vacc-c5, i.e., the upside potential from partnering or licensing remains with the company.